Palisade Bio (PALI) news
Recent news
Palisade Bio reports second quarter 2026 financial results and highlights continued advancement of Pali-2108 into Phase 2 development
AInvest Wire · Aug 10, 2026Palisade Bio Q2 operating income USD -11.698 million
AInvest Wire · Aug 10, 2026Palisade Bio - Ascentra-UC enrollment expected H2 2026; primary efficacy results expected H2 2027
AInvest Wire · Jun 29, 2026New York Times not liable for allegedly defaming Sarah Palin, Manhattan federal jury finds
New York Times not liable for allegedly defaming Sarah Palin, Manhattan federal jury finds A Manhattan federal jury has ruled that the New York Times is not liable for defamation in a lawsuit brought by former Alaska Governor Sarah Palin. The verdict comes after a retrial stemming from procedural…
AInvest Wire · Apr 22, 2025ImportantPalisade Bio stock slides 8% amid colitis drug presentation
Palisade Bio stock slides 8% amid colitis drug presentation The stock price of Palisade Bio, a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, experienced a decline of 8% following the presentation of positive preclinical data…
AInvest Wire · Apr 10, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.